Related Experiment Video

Updated: Jun 21, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Clinical development of inhibitors of the insulin-like growth factor receptor in oncology

Antonio Gualberto1, Michael Pollak

  • 1Pfizer Oncology, 50 Pequot Ave. MS6025-A3266, New London, CT 06320, USA. antonio.gualberto@pfizer.com

Current Drug Targets
|August 12, 2009
PubMed

Insights

Targeting the insulin-like growth factor I receptor (IGF-IR) pathway shows promise for cancer treatment. Early trials indicate good safety and effectiveness, supporting further research in various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The insulin-like growth factor I receptor (IGF-IR) pathway is crucial for cancer growth, survival, and therapeutic resistance.
  • Decades of research suggest targeting IGF-IR as a potential cancer treatment strategy.
  • Numerous compounds targeting IGF-IR are in development, with many in clinical trials.

Purpose of the Study:

  • To review the preclinical rationale for targeting the IGF-IR and related components of the IGF-I system.
  • To summarize early clinical results, biomarker strategies, and lessons learned for future study designs.
  • To explore the role of the IGF axis in tumor initiation and progression.

Main Methods:

  • Review of preclinical data supporting IGF-IR targeting.
  • Analysis of early-phase clinical trial outcomes (Phase I and II).
  • Examination of biomarker approaches used in clinical studies.

Main Results:

  • Early clinical trials demonstrate an acceptable safety profile for IGF-IR targeting agents.
  • Pharmacodynamic evidence confirms receptor engagement.
  • Single-agent activity has been observed in Phase I trials.
  • A Phase II study showed improved outcomes for non-small cell lung cancer patients treated with an anti-IGF-IR antibody plus chemotherapy.

Conclusions:

  • Targeting the IGF-IR pathway is a promising therapeutic strategy in oncology.
  • Early clinical data support the continued investigation of IGF-IR inhibitors across diverse cancer types.
  • Further research is warranted to optimize treatment strategies and understand the IGF axis in cancer.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...